<DOC>
	<DOC>NCT02928393</DOC>
	<brief_summary>This Phase 2a, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Radiologic assessment confirming an acute middle cerebral artery ischemic stroke Index stroke occurred within the past 34 days Inpatient males and females Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (&lt;/=) 35 Sufficient speech, vision and hearing to participate in study evaluations The presence of a reliable caregiver National Institute of Health Stroke Scale (NIHSS) greater than (&gt;) 20 Severe aphasia that prevents a participant from adequately completing study assessments Significant deficit from prior strokes or preexisting motor deficit History of epilepsy, neurosurgery, severe head trauma or central nervous system (CNS) infections that have residual symptomatology or have required treatment in the last 12 months Known or suspected clinical seizure postindex stroke History of preexisting dementia or use of medications for dementia History of clinically significant preexisting psychiatric conditions within 12 months prior to stroke Due to undergo carotid surgery within the next 4 months Enrollment/participation in any interventional study (clinical trial) involving an investigational drug (unapproved) or nondrug treatment within the prior 3 months or 6 times the halflife (whichever is longer) Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments Contraindication to Magnetic Resonance Imaging (MRI) or conditions which render interpretation of MRI difficult</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>